Buyer profile

Gilead Sciences, Inc.

Every published deal in the Exit Mode archive where this buyer appears on the acquiring side.

Country

United States

Deal count

2

Buyer type

Corporate / other

Aggregate disclosed value

Not stated

6 March 2026CompletedHealthcare

Gilead Sciences, Inc. to acquire Arcellx, Inc.

Gilead Sciences, Inc. and Arcellx, Inc. entered the Exit Mode archive.

Buyer: Gilead Sciences, Inc.
Target: Arcellx, Inc.
Deal value: USD 7,100,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

12 February 2024CompletedHealthcare

Gilead Sciences, Inc. to acquire CymaBay Therapeutics, Inc.

Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. entered the Exit Mode archive.

Buyer: Gilead Sciences, Inc.
Target: CymaBay Therapeutics, Inc.
Deal value: USD 4,300,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

Keep browsing

Explore the archive from another angle

Explore sectors

Telecommunications Industrials Other Education Aerospace & Defence Financial Services

Browse by deal type

strategic acquisition unknown merger of equals minority stake going private asset sale

Browse by region

United States Europe United Kingdom Other regions

Browse by country

United States Germany United Kingdom Switzerland Spain South Africa

Browse by stage

In review Completed Announced Abandoned

Year archives